How to Choose the Right CDMO for Early-stage Molecules:
A Practical Guide for Pharma &
Biotech Innovators
Early-stage drug development is defined by uncertainty but your CDMO selection should not be.
For a promising molecule moving from discovery into preclinical development, IND-enabling studies or first-in-human trials, the Contract Development and Manufacturing Organization (CDMO) is far more than a service provider. The right partner can help translate scientific potential into a manufacturable, scalable and regulator-ready product. The wrong one can introduce avoidable delays, technical rework, and supply risk and capital burn at the point when every month matters.
This is especially important in an industry where the odds are already demanding. Research suggests that only around 10% to 20% of candidates entering clinical development ultimately receive marketing approval, while one recent analysis of leading R&D companies reported an average first-approval likelihood of 14.3%. Phase II remains a major inflection point, with only about 32% of candidates progressing from Phase II to Phase III in that analysis.
The takeaway is clear: early development decisions must preserve optionality, accelerate learning and reduce avoidable risk. Choosing the right CDMO is one of the most consequential decisions on that journey.
Why CDMO Selection Matters So Much in Early Development
At the early stage, a molecule is rarely “manufacturing-ready.” It may have limited process understanding, poor solubility, stability concerns, challenging impurity profiles, uncertain formulation requirements or a supply chain built around a small number of starting materials.
A capable early-stage CDMO helps answer the questions that determine whether a program can move forward:
- Can the route be made safer, shorter or more robust?
- Can critical impurities be understood and controlled?
- Is the API suitable for the intended dosage form?
- Can the process scale from grams to kilograms and later to commercial volumes?
- What CMC data will be required for an IND or CTA filing?
- Which risks should be addressed now, and which can be managed through a phase-appropriate strategy?
This is why the lowest-cost quote is rarely the best decision criterion. A low initial development price can become expensive if the partner lacks the technical depth, analytical capability or project-management discipline needed to prevent rework later
The global CDMO market reflects this strategic shift. Estimates place the pharmaceutical CDMO market at approximately US$ 166 billion in 2025, with projections reaching nearly US$ 294 billion by 2033, driven by continued outsourcing across development and manufacturing. For sponsors, this growth creates more choice but also makes differentiation more important.
1. Start with Molecule-Platform Fit - The first question should be simple: Has this CDMO successfully handled molecules with challenges similar to mine?
“Small molecule capability” is too broad to be meaningful. An early-stage oncology compound, a highly potent API (HPAPI), a peptide building block, a poorly soluble oral candidate and a sterile injectable each require different expertise, containment strategies, analytical methods and development pathways.
Look for evidence of fit in areas such as:
- Chemistry complexity and route scouting experience
- High-potency handling and containment systems
- Chiral chemistry, flow chemistry or biocatalysis capabilities
- Salt selection, polymorph screening and particle engineering
- Oral solid, liquid, injectable or complex formulation expertise
- Stability-indicating analytical method development
- Experience with controlled substances, hazardous chemistry or sensitive intermediates
A strong CDMO should not simply say, “We can do it.” It should be able to explain how it would approach your molecule, identify likely development risks and outline the decisions that must be made before scale-up.
2. Assess Development Strength Before Manufacturing Scale - Large reactors and impressive capacity can be reassuring but early-stage programs need scientific problem solving before they need commercial-scale output.
The best early-development partners combine process chemistry, analytical development, formulation science, regulatory CMC knowledge and manufacturing expertise from the beginning. This integrated approach can reduce handoffs, shorten decision cycles and prevent the “throw it over the wall” model where development and manufacturing teams operate in silos.
Ask prospective CDMOs:
- Who will lead process development and analytical development?
- How early are manufacturing engineers involved in scale-up planning?
- Can the same team support the program through clinical phases?
- How are deviations, failed experiments and technical learnings documented?
- What does a phase-appropriate control strategy look like for this program?
Early-stage development is not about achieving perfection immediately. It is about generating the right data at the right time. A CDMO that understands this distinction can help sponsors avoid both underdevelopment and unnecessary overdevelopment.
3. Evaluate Analytical and CMC Readiness Early - Analytical development is often underestimated until it becomes the bottleneck.
Without robust, stability-indicating methods, sponsors can struggle to understand purity, degradation pathways, residual solvents, genotoxic impurities, potency and batch-to-batch consistency. These are not just technical issues; they directly affect filing readiness, clinical supply release and regulatory confidence.
A CDMO should be able to support a clear analytical and CMC roadmap covering:
- Method development and qualification
- Impurity identification and control strategies
- Forced degradation and stability studies
- Reference-standard management
- Raw-material and starting-material justification
- Specifications appropriate for the clinical phase
- Documentation for IND, CTA or IMPD submissions
The U.S. Food and Drug Administration notes that Phase II studies can run from several months to two years and typically involve a few hundred patients. Delays in material supply or CMC documentation during this period can have a disproportionate impact on development timelines and investor confidence
4. Look for Scalability without Premature Over-engineering - A process that works in a laboratory flask is not automatically ready for a 100 kg campaign. Early-stage sponsors should choose a CDMO that can think ahead without forcing a commercial-scale solution too soon
The goal is to build a credible scale-up pathway and this means understanding:
- Availability and quality of key starting materials
- Hazard assessment and process safety
- Equipment compatibility at different scales
- Yield, throughput and solvent-use implications
- Isolation and drying behavior
- Cleaning and containment requirements
- Tech-transfer risks between development and GMP manufacturing
The right CDMO will help you develop a process that is fit for the next milestone while retaining a practical route to later clinical and commercial manufacturing.
5. Examine Quality Culture and Regulatory Track Record - For early-stage molecules, “GMP-ready” simply is not enough. Sponsors need confidence that the CDMO’s quality systems are embedded in day-to-day execution.
Evaluate the organization’s inspection history, data-integrity culture, deviation management, change-control discipline and ability to produce complete, traceable documentation. Ask how quality assurance is involved in development activities and not only in batch releases.
A strong quality culture should be visible in how the CDMO communicates risk. The best partners raise the challenges early, explain the potential impact and bring forward practical mitigation options.
6. Choose a Partner That Communicates like an Extension of Your Team - Technical capability can be undermined by poor communication.
For lean biotech teams, responsiveness and transparency are often as important as laboratory infrastructure. A good CDMO provides clear project governance, realistic timelines, regular technical updates and direct access to scientific decision-makers. Before signing, clarify:
- Who is the dedicated project manager?
- How often will project reviews occur?
- How are scope changes managed?
- What is the escalation process for critical issues?
- Will your team have access to the scientists doing the work?
- How are timelines, costs and risks reported?
A CDMO relationship should feel collaborative, not transactional. The right partner challenges assumptions constructively and helps the sponsor make faster, better-informed decisions.
7. Think Beyond the First Batch - The most effective CDMO partnerships are built around the next value inflection point as relationships are moving from being only transactional in nature.
For an early-stage molecule, that may mean supporting route optimization today, IND-enabling material tomorrow, Phase I and II clinical supply next, and eventual commercial readiness thereafter. Choosing a partner with integrated capabilities can reduce the operational friction of changing suppliers as the molecule advances.
This does not mean every program needs a single CDMO for life. It means the selected partner should offer a credible growth path, technical continuity and strategic flexibility.
The Right CDMO Is a Risk-Reduction Strategy
Selecting a CDMO for an early-stage molecule is ultimately a decision about risk management. The strongest partner is not necessarily the most familiar name; rather it combines molecule-specific expertise, phase-appropriate development, analytical depth, quality discipline, scalable infrastructure and transparent collaboration. At a time when clinical success remains difficult and development timelines are under constant pressure, sponsors need partners that can turn complexity into progress.
At Lupin Manufacturing Solutions, we support innovators with integrated CDMO capabilities spanning building blocks and intermediates, drug substance development and manufacturing, drug product development, analytical services and specialized modalities. Our teams work collaboratively to help early-stage programs build the technical, quality and supply-chain foundation needed for the next milestone.